IP Library Granted Patent US 9,334,540
Granted Patent B2
US 9,334,540 · App. 14/063,534 · Granted May 10, 2016

Methods and compositions for diagnosing complications of pregnancy

Inventors: Yaron Goren (Kefar Hass, IL); Shlomit Gilad (Gani Hadar, IL); Moshe Hod (Herzelia, IL); Yariv Yogev (Ramat Aviv, IL)
Assignees: Rosetta Genomics Ltd.; MOR Research Applications
C12Q1/6883C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,334,540
App. No.
14/063,534
Granted
May 10, 2016
Kind
B2
Abstract

The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.

Claims (5)

1. A method for determining whether a pregnant female subject is at risk of developing preeclampsia, said method comprising: obtaining a test biological sample from said female subject and a control biological sample from a pregnant woman of same gestational age with no clinical or laboratory evidence of hypertensive disorder of pregnancy; extracting RNA from the test biological sample and the control biological sample; determining by real-time PCR an expression level of SEQ ID NO: 10 in the test biological sample, wherein said real-time PCR comprises contacting the test biological sample with forward and reverse primers, wherein the forward primer comprises 15-21 nucleotides identical to a DNA sequence equivalent to SEQ ID NO: 10; comparing the expression level of SEQ ID NO: 10 in the test biological sample and the control biological sample; and determining whether said pregnant female is at risk of developing preeclampsia based on increased expression of SEQ ID NO: 10 in the test biological sample relative to the control biological sample.

2. The method of claim 1 , wherein said biological sample is selected from the group consisting of bodily fluid and a tissue sample.

3. The method of claim 2 , wherein said bodily fluid sample is serum sample.

4. The method of claim 2 , wherein said tissue is a fresh, frozen, fixed, wax-embedded or formalin fixed paraffin-embedded (FFPE) tissue.

5. The method of claim 4 , wherein said tissue sample is placenta sample or uterine myometrium sample.

Assignments (2)
SECURITY INTEREST Recorded Dec 15, 2017
From: ROSETTA GENOMICS INC.; ROSETTA GENOMICS LTD; MINUET DIAGNOSTICS, INC.; CYNOGEN INC.
To: GENOPTIX, INC.
Reel/Frame 044899/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2016
From: GOREN, YARON; GILAD, SHLOMIT; HOD, MOSHE; YOGEV, YARIV
To: ROSETTA GENOMICS LTD.; MOR RESEARCH APPLICATIONS
Reel/Frame 037451/0804 →
Continuity (4)
Division 12864424
Provisional Application 61040671 · Mar 30, 2008
Provisional Application 61023859 · Jan 27, 2008
Related Publication 20140087967A1 · Mar 27, 2014